Press Releases
Mar 29, 2021

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that a Phase 3 confirmatory trial of XOSPATA® (gilteritinib) in patients with relapsed...

Mar 26, 2021

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced today that the U.S. Food and Drug Administration (FDA) approved Myrbetriq® (mirabegron...

Mar 26, 2021

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced today the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...

EXPLORE ALL US PRESS RELEASES

Articles
Sep 17, 2020

As part of our ranking among Working Mother Magazine’s Top 10 companies and among the top 30 for working dads, we selected Dominique Talbert, director Scientific Publications, Medical &...

Mar 7, 2019

An Interview with Astellas US President Percival Barretto-Ko recently shared his day-to-day experience in his role as well as some of the key focus areas that are critical to the future of...

Apr 10, 2019

By Yoshitsugu Shitaka, President, Astellas Institute for Regenerative Medicine Astellas strives to be on the forefront of healthcare change and our work in regenerative medicine is a clear example...

EXPLORE ALL ARTICLES

Stay Connected

Get only the email alerts you want.

Subscribe

Media Contacts

corporate.communications@astellas.com

800-888-7704
(press menu option 5, then option 2)
This line is monitored between 8:00am-4:30-pm Central Time M-F

For inquiries during non-business hours, please contact us

 

Astellas on Twitter
Download Fact Sheet
Sustainability
Investors
Explore U.S. Products